David Cameron today visited the Oxford Drug Discovery Institute (ODDI) in connection with his role as President of Alzheimer’s Research UK.
The ODDI was established five years ago as part of Alzheimer’s Research UK’s Drug Discovery Alliance (DDA) – an ambitious research initiative that brings together three dedicated Drug Discovery Institutes, based at the University of Oxford, the University of Cambridge and University College London.
During the visit, Mr Cameron met with the heads of the ODDI and was given an extensive tour of the high content imaging suite, the chemistry lab and the enzyme assay section. During his meeting with the heads of the ODDI, Mr Cameron received a briefing on the science behind the research, as well as the progress being made in Alzheimer’s research. Pro-Vice-Chancellor of Oxford University, Professor Chas Bountra, said that “The past five years have been incredibly interesting and exciting for the DDA, but the next five years are going to be even more so”.
Mr Cameron stated that “The work being done across the 3 Drug Discovery Institutes is crucial for the future. Collaboration in dementia research is vital to the development of effective treatments – and the ODDI, along with its partners at Cambridge and UCL, is an example of collaboration at its best.”
More information about Alzheimer’s Research UK can be found at: https://www.alzheimersresearchuk.org